NVCT · Nuvectis Pharma, Inc.
$19.08
+1.05 (+5.82%)
At close · Jul 21
Market Cap
$510.09M
Shares
26.53M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Ron Bentsur | CEO | $2,588,526 |
| Enrique Poradosu | Chief Scientific & Business Officer | $1,586,241 |
| Shay Shemesh | Chief Development and Operations Officer | $1,586,241 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Enrique Poradosu | Chief Scientific & Business Officer | $1,814,813 |
| Shay Shemesh | Chief Development and Operations Officer | $1,814,813 |
| Ron Bentsur | CEO | $1,157,639 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Ron Bentsur | CEO | $2,690,725 |
| Enrique Poradosu | Chief Scientific & Business Officer | $1,563,400 |
| Shay Shemesh | Chief Development and Operations Officer | $1,563,400 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Ron Bentsur | CEO | $1,694,010 |
| Enrique Poradosu | Chief Scientific & Business Officer | $970,272 |
| Shay Shemesh | Chief Development and Operations Officer | $950,468 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Ron Bentsur | CEO | $384,018 |
| Shay Shemesh | Chief Development and Operations Officer | $219,139 |